| 2023-12-04 | +2.19 % |
|
| 2023-11-30 | +1.86 % |
|
| 2023-11-14 | +4.23 % |
|
| 2023-11-13 | +6.49 % |
|
| 2023-10-26 | -1.41 % |
|
| 2023-10-19 | +3.66 % |
- DaVita HealthCare Partners Inc (NYSE:DVA) stock went up 3.66% because it was one of the top performers on the S&P 500.
- DaVita (DVA) stock went up by 3.66% due to the growing popularity of weight-loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, which may benefit some kidney disease patients and lead to a potential boost in revenues for dialysis services providers like DaVita.
- The article discusses the potential impact of weight-loss drugs on different sectors, including retailers, food and beverage companies, dialysis service providers, medical device makers, and drug distributors. It mentions that the popularity of weight-loss drugs such as Wegovy and Ozempic could potentially affect sales in these sectors. As a result, companies like Conagra, Walmart, PepsiCo, Fresenius Medical Care, Davita, Johnson & Johnson, Abbott Laboratories, Insulet Corp, and Intuitive Surgical are monitoring the situation and assessing the impact on their businesses. The article does not directly explain why Davita's stock went up by 3.66% the previous night.
|
| 2023-10-18 | +3.09 % |
|
| 2023-10-13 | -0.8 % |
|
| 2023-10-12 | -2.77 % |
|
| 2023-10-11 | -16.86 % |
|
| 2023-09-19 | +2.2 % |
|
| 2023-09-14 | -2.71 % |
|
| 2023-09-13 | +4.09 % |
|
| 2023-09-11 | +0.74 % |
|
| 2023-09-06 | +2.32 % |
|
| 2023-09-05 | -6.16 % |
|
| 2023-08-22 | -0.23 % |
|
| 2023-08-18 | +0.91 % |
|
| 2023-08-17 | -3.5 % |
|
| 2023-08-07 | +3.56 % |
|
| 2023-07-13 | -0.95 % |
|
| 2023-06-27 | -1.18 % |
|